Market Closed -
Japan Exchange
02:00:00 2024-05-17 am EDT
5-day change
1st Jan Change
408
JPY
-0.49%
-1.45%
-23.02%
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022
November 12, 2021 at 04:00 am EST
Linical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2022. For the year, the company expects net sales to be JPY 10,700 million. Operating income to be JPY 683 million. The forecast of ordinary income and profit attributable to owners of parent are undetermined since there are many uncertain factors such as exchange rate fluctuations.
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Apr. 12
CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses
Feb. 21
MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
Feb. 14
CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules
23-09-26
MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023
22-12-27
CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023
22-12-27
CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services
22-11-17
MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-11-14
CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index
22-09-19
CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022
22-02-14
CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022
22-02-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
More about the company
Average target price
500
JPY
Spread / Average Target
+22.55%
Consensus
1st Jan change
Capi.
-23.02% 59.29M -0.09% 42.12B +49.62% 42.05B -4.96% 29.18B +11.18% 26.02B -21.95% 18.9B +8.61% 13.21B +24.73% 12.17B +28.31% 12.16B -6.26% 11.42B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1